COVID-2019 vaccine - AuraVax Therapeutics
Latest Information Update: 01 Aug 2024
At a glance
- Originator AuraVax Therapeutics
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 30 Jul 2024 Pharmacodynamics data from a preclinical trial in COVID-2019 infections released by AuraVax Therapeutics
- 19 Sep 2023 Pharmacodynamics data from a preclinical studies in COVID-2019 infections (Prevention) released by AuraVax Therapeutics
- 07 Mar 2023 AuraVax Therapeutics announces intention to file an investigational new drug application for COVID-2019 vaccine